executive team, lead by Dr. Nicholas Plotnikoff
, met with Skystar's
executive management and top research team in Xi'an, China in early January and signed a three-year agreement whereby TNI-Penta will provide MEK Active Pharmaceutical Ingredients (API), requisite technology, intellectual property rights, and technical and consulting services to Skystar
to help in performing tests in a controlled environment to evaluate the safety, duration of immunity, minimum effective dosage and protective efficacy of the newly developed drugs containing MEK API.Once the products have successfully passed all testing stages, Skystar
will file for government approval for mass production and sale throughout China.TNI-Penta
will receive an average of 9% of the gross revenues realized from sale of any new product developed through this joint venture.Dr. Nicholas Plotnikoff, Chairman and CEO of TNI-Penta, commented, "Both Dr. Huang, President of Penta Biotech, and I are very excited and eagerly awaiting the results of the initial testing phase of the potential applications of our cytokine met-enkephalin to a variety of veterinary pharmaceutical uses.
With Dr. Plotnikoff
team's input and assistance, we are seeking to revolutionize our industry by developing new and highly effective products using methods and technologies never before used in this area."
...TNI-Penta is a joint venture between TNI Pharmaceuticals, Inc. and Penta Biotech, Inc. and is led by renowned scientist Dr. Nicholas Plotnikoff.
...TNI-Penta's Chairman and CEO, Dr. Nicholas Plotnikoff's principal research interests are in the areas of psychoneuroimmunology with special emphasis on stress hormones and cytokines (enkephalins-endorphins).His
current research has been focused on the clinical effects of methionine enkaphalin in the treatment of cancer and AIDS patients.